FRAMINGHAM, Mass. and SYDNEY, Sept. 28, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that clinical data for the HeartWare® Ventricular Assist System will be presented on Sunday, October 2, 2011 at the 25th EACTS Annual Meeting in Lisbon, Portugal.
A presentation by Mark S. Slaughter, M.D., entitled HeartWare®: Results of the ADVANCE Bridge to Transplant Trial, is scheduled for Sunday, October 2, 2011, at noon local time (7:00 a.m. U.S. Eastern Daylight Time) in Auditorium 1 of the Lisbon Congress Centre. Dr. Slaughter, a principal investigator for HeartWare's ADVANCE trial, is Professor and Chief in the Division of Thoracic and Cardiovascular Surgery and Director of the Mechanical Assist Device and Heart Transplant Program at the University of Louisville. The presentation will include clinical data from ADVANCE, as well as from the Continued Access Protocol for that study.
Investor Breakout Session and Webcast
Following the data presentation at EACTS, HeartWare management will host an investor breakout session with Dr. Slaughter, which will be available via audio webcast and conference call, at 2:00 p.m. local time (9:00 a.m. U.S. Eastern Daylight Time) on October 2, 2011 in Room 1.06 of the Lisbon Congress Centre.
The audio from the meeting will be available to the public via webcast through the Company's website at (http://www.heartware.com/) by selecting "EACTS Investor Meeting" under the section titled "Corporate Presentations" on the home page. A replay of the audio webcast will be available through the above weblink shortly following completion of the investor meeting. The audio for the meeting may also be accessed by dialing 1-800-215-2410 five minutes prior to the scheduled start time and referencing passcode 46162598. For callers outside the United States, please dial +1-617-597-5410 and reference passcode 46162598.
Slides from the presentation at EACTS will be available following the presentation on the Company's International website (http://www.heartware.com) by selecting the International region, then Clinicians, then Clinical Trials.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol and is not yet commercially available. For additional information, please visit the Company's website at www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.
